Araceli Casado

Ms. Araceli Casado


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2025 in Viruses
Verified
Journal Article
Open access
PDF file
JCJoaquin Cabezas
Joaquin Cabezas
AAAntonio Aguilera
Antonio Aguilera
FGFederico Garcia
Federico Garcia
RDRaquel Domínguez-Hernández
Raquel Domínguez-Hernández
ACAraceli Casado
Araceli Casado
JCJavier Crespo
Javier Crespo
In 2022, scientific societies agreed on a document with recommendations for a comprehensive diagnosis of viral hepatitis (B, C, and D). The aim was to evaluate the situation in Spain regarding the comprehensive diagnosis of viral hepatitis in a single blood draw before it is recommended. A panel of experts prepared a structured survey directed at hospitals (public or private with teaching accreditation) with ≥200 beds (sent 20 October 2022, closed 1 December 2022). The response rate was 61% (79/129; 52 hospitals with >500 beds). Among the participating hospitals, all could perform tests for HBsAg, anti-HCV, and HIV serology; 94% could perform PCR testing for HCV, 63% could test for anti-HDV, and 28% could test for HDV-RNA (67% [53/79] outsourced this testing). Point-of-care (POC) testing availability was low (24%), with 84% of these tests being supervised by the reference microbiological laboratory and the results being registered in the patients’ medical history. Ninety percent of the centers carried out the diagnosis in a single step (99% HCV, 70% HBV, 48% HDV, and 44% HBV-HDV). In addition, 77% used some communication strategy when an active infection was encountered (100% HCV, 49% HBV, and 31% HDV). Only 20% had an automated system for scheduling a specialist physician appointment. Most hospitals had the means for a comprehensive diagnosis of viral hepatitis in a single sample, but <50% could test for HBV/HDV. Alerts for continuity of care were available for HCV, but not HBV or HDV. POC device implementation is important for decentralized testing.

30 May 2023 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
CVCarlos Vallejo
Carlos Vallejo
IJIsidro Jarque
Isidro Jarque
Jesús FortúnJesús Fortún
Jesús Fortún
ACAraceli Casado
Araceli Casado
JPJavier Pemán
Javier Pemán
Recent advances in the treatment of hematologic malignancies have improved the overall survival rate, but the number of patients at risk of developing an invasive fungal infection (IFI) has increased. Invasive infections caused by non-Candida albicans species, non-Aspergillus molds, and azole-resistant Aspergillus fumigatus have been increasingly reported in recent years. We developed a cross-sectional multicenter survey which involved a total of 55 hematologists and infectious disease specialists from a total of 31 Spanish hospitals, to determine the most frequent strategies used for the management of IFIs. Data collection was undertaken through an online survey which took place in 2022. Regarding key strategies, experts usually prefer early treatment for persistent febrile neutropenia, switching to another broad-spectrum antifungal family if azole-resistant Aspergillus is suspected, broad-spectrum azoles and echinocandins as prophylactic treatment in patients receiving midostaurin or venetoclax, and liposomal amphotericin B for breakthrough IFIs after prophylaxis with echinocandins in patients receiving new targeted therapies. For antifungals failing to reach adequate levels during the first days and suspected invasive aspergillosis, the most appropriate strategy would be to associate an antifungal from another family.

12 October 2023 in Medicina Clinica
Verified
Journal Article
Closed access
FFFrancisco Javier Castelbón Fernández
Francisco Javier Castelbón Fernández
MSMaría Barreda Sánchez
María Barreda Sánchez
ECElena Arranz Canales
Elena Arranz Canales
MCMaría Encarnación Hernández Contreras
María Encarnación Hernández Contreras
ISIsabel Solares
Isabel Solares
ENEncarna Guillén Navarro
Encarna Guillén Navarro

17 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
RZRafael Zaragoza
Rafael Zaragoza
ÁEÁngel Estella
Ángel Estella
XNXavier Nuvials
Xavier Nuvials
MPMireya Robles Plaza
Mireya Robles Plaza
ACAraceli Casado
Araceli Casado
Background: The objective was to identify management strategies of IFI in critically ill patients through a Spanish national survey. Methods: A cross-sectional multicentre survey among ICU specialist, experienced in IFI was performed (22-April-25-July 2024). The survey consisted of 13 questions with four closed answers. Results: Sixty-three experts from 51 hospitals of 16 regions completed the survey. 95% stated that, in high-risk patients with clinical suspicion of Pulmonary Aspergillosis (PA), request galactomannan in BAL to initiate treatment. In the treatment of patients with PA and influenza, 86% declared that isavuconazole and liposomal amphotericin B are recommended treatments and in high suspicion of aspergillus coinfection, 76% recommended empirical treatment waiting for microbiological confirmation. 90% declared that the use of Extracorporeal Membrane Oxygenation (ECMO) and Renal Replacement Therapies (RRT) could be associated with lower azole levels. Regarding intraabdominal candidiasis, 78% that physiopathological changes in critically ill patients, reduce their entry into the peritoneal fluid. Conclusion: The majority of the experts agreed (>80%) on: In suspicion of PA, Galactomannan in BAL to guide treatment is mandatory; In case of aspergillosis and influenza, isavuconazole and liposomal amphotericin B are the recommended treatments; The use of ECMO and RRT could be associated with lower azole levels.

5 May 2026 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
RZRafael Zaragoza
Rafael Zaragoza
ÁEÁngel Estella
Ángel Estella
XNXavier Nuvials
Xavier Nuvials
MPMireya Robles Plaza
Mireya Robles Plaza
ACAraceli Casado
Araceli Casado
Background: The objective was to identify management strategies of IFI in critically ill patients through a Spanish national survey. Methods: A cross-sectional multicentre survey among ICU specialists, experienced in IFI, was performed (22 April–25 July 2024). The survey consisted of 13 questions with four closed answers. Results: Sixty-three specialists from 51 hospitals of 16 regions completed the survey. 95% stated that, in high-risk patients with clinical suspicion of Pulmonary Aspergillosis (PA), galactomannan in BAL is performed to guide treatment. In the treatment of patients with PA and influenza, 86% declared that isavuconazole and liposomal amphotericin B are recommended treatments and in high suspicion of Aspergillus coinfection, 76% recommended empirical treatment waiting for microbiological confirmation. 90% declared that the use of Extracorporeal Membrane Oxygenation (ECMO) and Renal Replacement Therapies (RRT) could be associated with lower azole levels. Regarding intra-abdominal candidiasis, 78% that physiopathological changes in critically ill patients, reduce their entry into peritoneal fluid. Conclusions: The majority of the respondents agreed (>80%) on: In suspicion of PA, Galactomannan in BAL to guide treatment is mandatory; In case of aspergillosis and influenza, isavuconazole and liposomal amphotericin B are the recommended treatments; The use of ECMO and RRT could be associated with lower azole levels.